\
&
Contact us
\
&
Contact us
Published on | 2 years ago
Programmes Enhancing EU R&IPlease note that the following update was published regarding the call topic HORIZON-WIDERA-2024-ERA-01-05: Experimentation and exchange of good practices for value creation.
The Commission is considering to cancel the topic “HORIZON-WIDERA-2024-ERA-01-05: Experimentation and exchange of good practices for value creation”. The next amendment of the Work Programme will propose to re-introduce the topic with an updated description to be funded under a call in 2024.
Source: Funding and Tenders Portal
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Research Infrastructures Health Culture and society Security
In the context of simplification, the Commission has introduced the following substantial changes in the Standard Application Form (Version 5.0) for Horizon Europe Research & Innovation Actions (RIA) and Innovation Actions (IA) and Coordination and Support Actions (CSA): Simplified section 2.1 'Project's pathways towards impac... read more
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
